Telomir Pharmaceuticals (TELO) said Wednesday that preclinical findings showed that Telomir-1 reduces tumor size by 50% in a prostate cancer animal model using "highly aggressive" human prostate cancer cells.
Telomir-1 "actively suppresses cancer growth rather than promoting it, and protects against chemotherapy-induced toxicity and mortality when combined with Paclitaxel," a chemotherapy drug that is often linked with severe toxicity and side effects, the company said.
Telomir said it is advancing Telomir-1 in several indications in addition to oncology. Studies are assessing the drug in age-related diseases like age-related macular degeneration and Wilson's disease, the company said.
The company said it plans to file an investigational new drug application by the end of the year.
Telomir shares were up 4% in recent Wednesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.